Biorce is a Barcelona-based healthtech company that built Aika, an AI platform trained on over 1 million clinical studies to automate and improve clinical trial design, reducing design time and identifying regulatory and risk issues.
Investment Rounds
Capital activity and funding progression
Industries
Frequently Asked Questions
Where is Biorce located?
Biorce is located in Barcelona, Spain.
What industries does Biorce operate in?
Biorce operates in the following industries: healthtech, clinical trials, artificial intelligence.
How much total funding has Biorce raised?
Biorce has raised a total of $52,000,000.
Who are the investors in Biorce?
The investors in Biorce are: DST Global, Arthur Mensch, Albert Nieto, Paulo Rosado, Nik Storonsky.
What is the core mission of Biorce in the clinical trial space?
Biorce is dedicated to accelerating access to life-saving treatments by making clinical trials faster and more efficient. The company aims to cut both the time and cost of drug development by 50 percent through its AI-driven technology.
What is the Biorce AI platform, Aika, and how does it work?
Aika is an AI-native platform by Biorce that optimizes clinical trial design and operations. It uses a multi-modality approach and a vast database of historical trials to help teams create regulator-ready protocols in as little as 90 seconds.
How does Biorce distinguish its Aika platform from other AI solutions in the pharmaceutical industry?
Unlike many point solutions, Biorce offers an end-to-end platform built on a pool of over one million clinical trials. It provides explainable AI and predictive modeling to identify design issues and optimize site selection, rather than just automating single tasks.
How does Biorce manage to reduce clinical trial preparation time so significantly?
Biorce reduces preparation time by using artificial intelligence to automate complex tasks like protocol creation and site feasibility studies. This allows researchers to move from initial design to a finished protocol much faster than manual methods allow.
How does Biorce ensure that its AI-generated protocols comply with global regulatory requirements?
Biorce builds alignment with FDA and EMA rules directly into its AI architecture. The platform generates protocols that are already tailored to meet the strict standards of health authorities, which helps prevent delays during the review process.
Does the Biorce platform integrate with existing clinical research and data systems?
Yes, Biorce is designed to be compatible with the existing systems used by pharmaceutical companies and contract research organizations. This allows for a seamless flow of data and keeps trial operations efficient without requiring a complete overhaul of current tools.
What personal inspiration led to the founding of Biorce?
Biorce was founded by Pedro Coelho, who was inspired by his father's battle with a terminal illness. Seeing how long it took for new treatments to reach those in need, he committed to fixing the inefficiencies in the clinical trial industry.